Published in Haemophilia on May 01, 2005
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost (2009) 1.27
Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa. J Thromb Haemost (2012) 0.89
Decreasing the need for transfusion: infant cardiac surgery using hemodilution and recombinant factor VIIa. Pediatr Cardiol (2012) 0.87
Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost (2010) 0.85
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag (2007) 0.85
Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). J Blood Med (2012) 0.81
Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors. J Blood Med (2010) 0.79
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. Drug Des Devel Ther (2010) 0.79
rFVIIa transported from the blood stream into tissues is functionally active. J Thromb Haemost (2010) 0.78
Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography. Med J Islam Repub Iran (2015) 0.77
Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa. Drug Des Devel Ther (2011) 0.77
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients. Drug Des Devel Ther (2010) 0.77
Key issues in inhibitor management in patients with haemophilia. Blood Transfus (2013) 0.76
The expanding role of prophylaxis with recombinant activated factor VII. Blood Transfus (2012) 0.75
Animal models of FVIIa gene expression: their role in the future development of haemophilia treatment. Haemophilia (2010) 0.75
The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex. J Biol Chem (1988) 2.33
Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. Ventak CHF Investigators. J Am Coll Cardiol (2000) 2.03
Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol (2001) 1.52
Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood (1998) 1.51
PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost (1998) 1.48
Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. J Thromb Haemost (2003) 1.41
Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood (1997) 1.23
Developmental regulation of RNA transcript destabilization by A + U-rich elements is AUF1-dependent. J Biol Chem (1999) 1.19
Glycoprotein Ic-IIa functions as an activation-independent fibronectin receptor on human platelets. J Cell Biol (1988) 1.13
Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost (2007) 1.04
On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa. J Clin Invest (1987) 1.02
Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia (2006) 1.01
Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells. Cancer Res (1976) 1.01
Effects of cytochalasins B and D on alloxan inhibition of insulin release. Biochem Biophys Res Commun (1975) 0.97
Nitric oxide mediates interleukin-1-induced cellular cytotoxicity in the rat ovary. A potential role for nitric oxide in the ovulatory process. J Clin Invest (1993) 0.97
Absolute levels of some free amino acids in normal and biologically fractionated retinas. Invest Ophthalmol (1973) 0.96
Analysis of ENU-induced mutations at the Adh locus in Drosophila melanogaster. Mutat Res (1990) 0.95
Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost (2007) 0.94
Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol (1987) 0.92
Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia (2012) 0.92
Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia (2007) 0.92
Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia (2004) 0.87
Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia (2009) 0.86
Genetics of platelet reactivity in normal, healthy individuals. J Thromb Haemost (2009) 0.86
Heavy water slows the Gonyaulax clock: a test of the hypothesis that D2O affects circadian oscillations by diminishing the apparent temperature. Proc Natl Acad Sci U S A (1974) 0.83
Effects of insulin secretagogues on protein kinase C-catalyzed phosphorylation of an endogenous substrate in isolated pancreatic islets. J Biol Chem (1990) 0.82
The estrogen receptor is present in human megakaryocytes. Ann N Y Acad Sci (1994) 0.82
Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia (2006) 0.82
DNA sequence analysis of X-ray induced Adh null mutations in Drosophila melanogaster. Environ Mol Mutagen (1991) 0.81
Regulation of pancreatic islet-cell plasma membrane Ca2+ + Mg2+-ATPase by calmodulin. FEBS Lett (1982) 0.81
A human monoclonal autoantibody recognizes a neoantigen on glycoprotein IIIa expressed on stored and activated platelets. Blood (1987) 0.80
Sequence analysis of monoclonal antibodies derived from a patient with idiopathic thrombocytopenic purpura. Autoimmunity (1990) 0.79
von Willebrand factor: what is its role in the immune response in haemophilia? Haemophilia (2011) 0.79
The immunogenicity of platelet membrane glycoproteins. Transfus Med Rev (1987) 0.78
Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia (2014) 0.78
Right and left ventricular function after cardiac transplantation. Changes during and after rejection. Circulation (1991) 0.78
Human monoclonal autoantibody 2E7 is specific for a peptide sequence of platelet glycoprotein IIb. Localization of the epitope to IIb231-238 with an immunodominant Trp235. J Autoimmun (1991) 0.78
Concentration and determination of selenium from environmental samples. Anal Chem (1976) 0.77
Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura. Hematology (2007) 0.77
Isolation and characterization of human platelet glycoprotein IX. Biochem Biophys Res Commun (1988) 0.77
A human monoclonal autoantibody specific for human platelet glycoprotein IIb (integrin alpha IIb) heavy chain. Hum Antibodies Hybridomas (1990) 0.76
Activation of mechanical responses in leukocytes. Biorheology (1990) 0.76
Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia (2005) 0.76
The mechanism of zinc uptake in isolated islets of Langerhans. Diabetes (1979) 0.76
Immune thrombocytopenic purpura: why treat? J Pediatr (1999) 0.75
Nucleotide sequence of the human autoantibody 2E7 specific for the platelet integrin IIb heavy chain. J Autoimmun (1991) 0.75
Severe electrical burns in a hemophiliac wearing a medical alert neck chain. Clin Pediatr (Phila) (1994) 0.75
Microdetermination of manganese in airborne particulate samples by means of the ring-oven technique. Anal Chim Acta (1974) 0.75
Danazol fails to increase factor VIII or IX levels in a double-blind crossover study of patients with haemophilia A and B. Br J Haematol (1986) 0.75
The age and job satisfaction relationship: does its shape and strength still evade us? J Gerontol B Psychol Sci Soc Sci (1998) 0.75
Light microscopic and scanning electron microscopic retrieval analyses of implanted biomaterials retrieved from humans and experimental animals. J Oral Implantol (2001) 0.75
Nonmetallic fixation in elective maxillofacial surgery. AORN J (2000) 0.75
Combined Rh hemolytic disease and granulocyte alloimmunization causing prolonged agranulocytosis in a newborn infant. J Perinatol (1994) 0.75
Female voice communications in high level aircraft cockpit noises--part II: vocoder and automatic speech recognition systems. Aviat Space Environ Med (1998) 0.75
Molecular specificity of anti-IIb/IIIa human antibodies. Semin Thromb Hemost (1995) 0.75
Quantitative angiography of coronary artery dimensions 24 hours after rotational atherectomy. Am J Cardiol (1998) 0.75
Screening for von Willebrand disease in children: a case-control study. J Thromb Haemost (2011) 0.75
Painless urethral bleeding: an unusual presentation of Von Willebrand disease. Haemophilia (2003) 0.75
Validity of the CELF-R, TONI, and sit for children referred for auditory processing problems. J Clin Psychol (1995) 0.75
Repertoire cloning of a human IgG inhibitor of alpha IIB beta 3 function. The OG idiotype. Mol Immunol (1995) 0.75
Growth of neonatal rat uterine luminal epithelium on extracellular matrix. In Vitro Cell Dev Biol (1991) 0.75